Pharma Business - April 15, 2019
Proposed management changes at Moberg Pharma
The Board of Directors and Nomination Committee have proposed the appointment of Anna Ljung as the new CEO of Moberg Pharma, while current CEO Peter Wolpert will transition to a role as Executive Chairman of the Board of Directors. The divestment of the OTC business on March 29, 2019 represents a significant change for Moberg […]
Intellectual Property - May 3, 2018
US patent granted for Moberg Pharma
The United States Patent and Trademark Office (USPTO) has issued Patent No. US 9,956,211 which protects BUPI, currently in development for pain due to oral mucositis. This patent should provide protection through to 2032. The U.S. patent covers a method for the treatment of pain due to oral mucositis in cancer patients by locally administering […]
Acquisition - February 28, 2018
Moberg Pharma divests Balmex for $4.25 million
Moberg Pharma AB has entered into an agreement with Randob Labs to divest the brand Balmex for a total consideration of $4.25 million (34.6 million SEK) plus the inventory value at closing. The divestment is expected to result in a capital gain of circa $0.5 million (4.4 million SEK), enabling Moberg Pharma to further focus […]
In a new job - October 17, 2017
Torbjörn Wärnheim new member of Moberg Pharma’s management team
Moberg Pharma appoints Torbjörn Wärnheim, Director Pharmaceutical Innovation and Development, as a member of Moberg’s Management Team. Wärnheim has had this position at Moberg Pharma since 2013. Prior to his position with Moberg, Torbjörn Wärnheim was Vice President R&D at Fresenius Kabi. In addition to this he has held senior level positions at ACO HUD […]
Intellectual Property - September 4, 2017
Patent granted for Moberg Pharma’s BUPI
Moberg Pharma announces that the Canadian Patent Office has issued Patent No. 2 860 373 which protects BUPI, currently in development for pain due to oral mucositis. The Canadian patent covers the use of a lozenge comprising a local anesthetic, e.g. bupivacaine, in a number of different indication, including treatment of pain due to oral […]
Agreement - August 21, 2017
Moberg Pharma divests Fiber Choice
Moberg Pharma has entered into an agreement with Caret Pharma LLC. to divest the brand Fiber Choice for a total consideration of $6.7 million plus the inventory value at closing. The divestment is expected to result in a capital gain of circa $1.6 million. Divesting the brand enables Moberg Pharma to further focus resources on […]
